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ABSTRACT 
Alport syndrome is a clinically heterogeneous, progressive nephropathy caused by 
mutations in collagen IV genes, namely COL4A3 and COL4A4 on chromosome 2 and 
COL4A5 on chromosome X. The wide phenotypic variability and the presence of 
incomplete penetrance suggest that a simple Mendelian model cannot completely explain 
the genetic control of this disease. Therefore, we explored the possibility that Alport 
syndrome is under digenic control. Using massively parallel sequencing, we identified 11 
patients who had pathogenic mutations in two collagen IV genes. For each proband, we 
ascertained the presence of the same mutations in up to 12 members of the extended 
family, for a total of 56 persons studied. Overall, 23 mutations were found. Individuals with 
two pathogenic mutations in different genes had a mean age of renal function deterioration 
intermediate with respect to the autosomal dominant form and the autosomal recessive 
one, in line with molecule stoichiometry of the disruption of the type IV collagen triple helix. 
Segregation analysis indicated three possible digenic segregation models: i) autosomal 
inheritance with linked mutations in trans mimicking recessive inheritance (5 families); ii) 
autosomal inheritance with linked mutations in cis mimicking dominant inheritance (2 
families); and iii) unlinked autosomal and X-linked inheritance having a peculiar 
segregation (4 families). This pedigree analysis provides evidence for digenic inheritance 
of Alport syndrome. Clinical geneticists and nephrologists should be aware of this 
possibility in order to more accurately assess recurrence risk, predict prognosis and 
identify other family members at risk.   
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Introduction 
Alport syndrome is an inherited nephropathy characterised by haematuria, 
proteinuria, progressive renal failure and ultrastructural lesions of the glomerular basement 
membrane, often associated with sensorineural deafness and ocular lesions.1 The primary 
defect resides in one of the alpha chains of type IV collagen produced by podocytes; the 
alpha chains assemble into a heterotrimeric triple helix (α3, α4 and α5) to create the three-
dimensional network of the basement membrane.2 The alpha 3 and alpha 4 chains are 
encoded by COL4A3 and COL4A4 genes, located head-to-head on chromosome 2, while 
the alpha 5 chain is encoded by COL4A5 on chromosome X. All three main models of 
Mendelian inheritance have been demonstrated in Alport syndrome: X-linked 
semidominant, autosomal recessive, and autosomal dominant.3,4,5 X-linked semidominant 
inheritance is associated with mutations in COL4A5, while autosomal recessive and 
dominant inheritance patterns are associated with one or two mutations in either COL4A3 
or COL4A4.4 
Mutant alleles of all three primary loci demonstrate variable expressivity. In 
particular, heterozygous COL4A5 females may be asymptomatic or have symptoms that 
range from microhaematuria alone to severe nephropathy leading to end-stage renal 
disease (ESRD).6 Similarly, heterozygous carriers of COL4A3 or COL4A4 mutations, 
irrespective of gender, may be asymptomatic, have microhaematuria (carriers of recessive 
disease) or may progress to ESRD, albeit at a later age (apparently dominant form)7,8.  A 
correlation between COL4A5 mutations and both the rate of progression to ESRD and the 
course of hearing loss and ocular lesions has been established in X-linked Alport 
syndrome but, even within a single family, there is variability in disease severity.6,9 Part of 
this variability may be due to a modifier effect of functional polymorphisms in the three 
collagen chains (of which COL4A3 and COL4A4 are particularly rich) or in other structural 
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proteins of the glomerular basement membrane, such as podocin.10 Clarification of this 
relevant clinical variability warrants further investigation. 
The wide phenotypic variability of patients with Alport syndrome and the presence 
of incomplete penetrance suggest that a simple Mendelian model is inadequate to explain 
the genetic control of this disease. An alternative genetic model that may apply to Alport 
syndrome is digenic inheritance. As explained by Shaffer in 2013, “inheritance is digenic 
when the variant genotypes at two loci explain the phenotypes of some patients and their 
unaffected (or more mildly affected) relatives more clearly than the genotypes at one locus 
alone”.11 Digenic inheritance has previously been demonstrated in diseases such as 
retinitis pigmentosa12 and left ventricular noncompaction cardiomyopathy.13 During the 
past few years, the extensive use of comparative genomic hybridisation and microarray 
technology (array CGH) has improved knowledge of two-loci diseases. In particular, it has 
recently been shown, in patients with various neuropsychiatric diseases, that an 
enrichment in copy number variants (CNVs) correlates with a more severe phenotype, i.e. 
a specific microdeletion both predisposes to neuropsychiatric phenotypes as a single 
event and exacerbates neurodevelopmental phenotypes in association with other deletions 
or duplications.14,15  
Research into the genetic causes of disease has been facilitated by the recent 
development of massively parallel sequencing techniques. This technology permit the 
sequencing of many genes simultaneously as a routine procedure, 5,7,16  and should 
accelerate the discovery and characterisation of disorders governed by digenic 
inheritance.11 In the past, when Sanger sequencing was the dominant method, it was 
common to stop analysis when a single pathogenic mutation was identified; this approach 
prevented the ascertainment of individuals with mutations in more than one collagen gene. 
Since 2011, we have been using massively parallel sequencing to evaluate the three 
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collagen IV genes in patients with Alport syndrome, and this approach permitted us to 
identify 11 people who have mutations in two genes. In this study, we examined the 
mutation pattern and clinical characteristics of these 11 patients and members of their 
extended families, to explore the possibility that Alport syndrome is under digenic control.  
Materials and methods 
Patients and families 
Genetic counselling was performed in six European institutes (University of Siena, 
Italy; Hôpital Necker – Enfants Malades, Paris, France; Guy’s Hospital, London, England; 
Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom; Maastricht 
University Medical Centre, The Netherlands; and Université Catholique de Louvain, 
Belgium) where patients with Alport syndrome were selected for mutation screening in the 
COL4A3, COL4A4 and COL4A5 genes according to clinical criteria.17 Eleven unrelated 
persons were found to have pathogenic mutations in more than one collagen gene. These 
patients (4 males and 7 females, 3–55 years old) and members of their extended families 
were recruited for the present study, allowing us to construct 11 pedigrees. Informed 
consent for clinical data sharing and DNA testing was obtained from each proband and 
family member; in case of minors, parental consent was obtained.  
From all persons recruited, we collected clinical data regarding: family status 
(proband or family relation), gender and age at inclusion (or death), kidney function 
(haematuria, proteinuria, chronic renal failure (CRF) or ESRD), hearing loss and ocular 
lesions; for all comorbidities we recorded age at diagnosis and eventual treatment. 
Moreover, we obtained a sample of peripheral blood in EDTA tubes when possible 
Genomic DNA, amplification and sequencing strategy 
Blood was stored frozen prior to the extraction of genomic DNA using QIAamp DNA 
Blood Kits (Qiagen, Hilden, Germany); this work was done at each institute for the families 
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recruited there. In Siena, genomic DNA was supplied directly from the institutional 
biobank. 
Genomic DNA from probands was assessed for mutations in COL4A3, COL4A4 
and COL4A5 by locus-specific amplification followed by massively parallel sequencing. 
Each participating institute amplified and sequenced the DNA for the probands it recruited. 
Briefly, the ALPORT MASTR kit (Multiplicom, Niel, Belgium) was used to amplify 149 
amplicons (representing 150 coding exons) of the three genes in a four-tube multiplex 
PCR reaction starting with about 4 X 50 ng genomic DNA. Amplification products were 
sequenced using either a GS Junior System (454 Life Sciences, Roche) or an Ion 
Personal Genome Machine (PGM; Life Technologies), as described below. Mutations of 
Probands 3, 4, 5, 7 and 9 have already been reported in Morinière et al.16 Genomic DNA 
from family members was analysed by Sanger sequencing to determine if these persons 
had the same mutations as the probands.   
GS Junior 454 sequencing 
Our strategy for sequencing the COL4A3, COL4A4 and COL4A5 genes on a GS 
Junior system has been reported.5 Briefly, amplification products were diluted and then 
reamplified with primers containing, at the 5’ end, a multiplex identifier sequence which 
barcodes the samples. The second PCR products for each proband were pooled in 
predefined proportions according to the ALPORT MASTR protocol (Multiplicom). These 
libraries were purified using Agencourt AMPure XP system (Beckman Coulter) and 
quantified using Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies), following the 
protocol of 454 Life Sciences (http://454.com/downloads/my454/documentation/gs-junior-
plus/454SeqSys_Amplicon-Library-Prep-MM_Apr2014.pdf). 
For GS Junior sequencing, libraries were diluted to a concentration of 1 X 107 PCR 
fragment molecules/µl, annealed to carrier beads (SeqCap EZ Pure Capture Bead Kit, 
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Roche NimbleGen) and clonally amplified by emulsion PCR (emPCR) according to the 
manufacturer’s protocol (http://454.com/downloads/my454/documentation/gs-
junior/method-manuals/GSJunioremPCRAmplificationMethodManualLib-
A_March2012.pdf). After amplification, the beads carrying single-stranded DNA templates 
were enriched, counted, and deposited into the PicoTiterPlate for sequencing 
(http://454.com/downloads/my454/documentation/gs-junior/method-
manuals/GSJuniorSequencingManual_Jan2013.pdf). Sequence reads were analysed 
using GS Amplicon Variant Analyzer, version 2.9. 
Ion PGM sequencing 
The strategy for sequencing the three collagen genes on an Ion PGM has recently 
been reported.16 Briefly, amplification products were diluted, reamplified using the 
universal primers included in ALPORT MASTR kit, and pooled in predefined proportions 
according to the ALPORT MASTR protocol. This pool was used to prepare a barcoded 
library compatible with the Ion PGM according to the protocol of Life Technologies 
(http://ioncommunity.lifetechnologies.com/community/login.jspa?referer=http://ioncommuni
ty.lifetechnologies.com/community/protocols-home).16 Libraries were purified using 
Agencourt AMPure XP system and quantified using Qubit dsDNA HS Assay Kit (Life 
Technologies).  
For Ion PGM sequencing, PCR fragments were diluted to 100 pM, annealed to 
carrier spheres (Ion Sphere Particles) and clonally amplified by emPCR using the Ion PGM 
Template OT2 200 kit (Life Technologies). Spheres carrying single-stranded DNA 
templates were transferred to Ion 314 chips for sequencing using the Ion PGM 
Sequencing 200 Kit v2. Data were processed using Torrent Suite software v4.0, while 
post-run analysis was conducted using Torrent Variant Caller plugin (v4.0-r72895). 
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In silico analyses  
Pathogenicity was ascertained if following criteria were met: non-polymorphic 
missense mutations or in-frame deletions involving key amino acids, such as glycine in the 
collagen Gly-X-Y triple helical domain, splice-site mutations, and truncating mutations. 
Pathogenicity of non-synonymous variations other than Gly substitutions was predicted 
using Alamut software v2.3 (Interactive Biosoftware, Rouen, France). To determine if the 
identified sequence variants were novel or had been previously reported, we searched in 
the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/), the Human Gene 
Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php)18, the Leiden Open Variation 
Database v2.0 Build 35 
(https://grenada.lumc.nl/LOVD2/COL4A/variants.php?select_db=COL4A3&action=search_
all&search_MutCol=%3E) and the ALPORT (COL4A5) database 
(http://www.arup.utah.edu/database/ALPORT/ALPORT_display.php?sort=2#alport; Last 
update: October 2013)19. 
Variants were described according to the COL4A3 reference sequence LRG_230 
(NM_000091.4), COL4A4 reference sequence LRG_231(NM_000092.4), and COL4A5 
reference sequence LRG_232(NM_000495), where nucleotide number 1 corresponds to 
the first base of the translation initiation codon, and using the nomenclature recommended 
by the Human Genome Variation Society.20 
Sanger sequencing and segregation analysis of pedigrees 
Pathogenic variants identified in probands were confirmed by direct Sanger 
sequencing. Sanger sequencing was also used to determine if the pathogenic variants 
were present in family members for whom genomic DNA was available. Briefly, genomic 
DNA was amplified using the primers and PCR conditions described for amplicon library 
preparation in Artuso et al.7 Sequencing was performed on an ABI Prism 310 genetic 
analyser (PE Applied Biosystems) and data were analysed with Sequencher software v4.9 
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(Gene Codes, Ann Arbor, USA). Genotypes of pedigrees were examined to determine if 
the COL4A3 and COL4A4 mutations on chromosome 2 were linked in cis or trans and to 
assess genotype-phenotype correlation. 
Results  
The study began with 11 Alport syndrome patients in whom massively parallel 
sequencing identified pathogenic mutations in two of the three collagen IV genes 
examined. In seven patients (Probands 1-7) there was a combination of mutations in 
COL4A3 and COL4A4, whereas in four (Probands 8-11) one or two mutations in COL4A4 
associated with a mutation in COL4A5. In no case were there simultaneous COL4A3 and 
COL4A5 mutations. Altogether, 23 unique mutations were found, including seven in 
COL4A3, 12 in COL4A4 and four in COL4A5 (Table 1). The mutations involved all 
domains of the collagen molecules, although the majority of missense mutations (11 of 13) 
affected the triple-helical collagenous domain and 11 missense mutations substituted a 
critical glycine residue in this domain. Overall, 13 mutations have been previously reported 
(among missense mutations six are already listed in dbSNP and four16 are pending 
assignment of a dbSNP reference ID) and 10 are novel.  
Between 1 and 12 family members were recruited for each proband, for an average 
of 4 members per family (Table 2). Therefore, the study considered a total of 56 persons 
(27 males and 28 females; gender missing for one person) from 5 to 80 years of age 
(exact age missing for 11 persons). Seven individuals were dead at the time of study. A 
wide range of kidney functionality was observed in the study population, ranging from 
normal (in 7 person), to micro- and macrohaematuria, proteinuria, CRF (in 6 persons) and 
ESRD (in 12 subjects leading to death in 4 cases). Hearing loss was recorded in 8 of 44 
persons for whom hearing test results were available, and ocular lesions were noted in 2 
of 6 persons for whom ophthalmological data were available. 
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Genomic DNA was available for 34 family members (all alive at the time of study). 
Sanger sequencing of this DNA revealed which family members had the same mutations 
as the probands (including which were heterozygous or hemizygous for only one mutation 
or compound heterozygous in only one gene), permitting us to explore the relationship 
between mutations and disease severity as well as to investigate the form of genetic 
transmission. Individuals with two mutations tended to be more severely affected than 
those with one mutation. The few cases of hearing loss and ocular lesions were observed 
only in persons with mutations in two genes, and, among the 5 persons with ESRD and 
sequencing data, the age at onset was lower in the 2 cases with two genes affected (25 
and 44 years) than in those with one gene affected (Family 4). 
Family 1 was identified first (Figure 1). In the proband (II:2) (Figure 1A), massively 
parallel sequencing (Figure 1B) revealed the presence of a COL4A4 glycine substitution 
inherited from the ascertained asymptomatic father and a splice site mutation in the 
COL4A3 gene inherited from the microhaematuric mother. The disruption of the terminal 
part of the triple helix in the alpha3 chain and the kink formed by the presence of the 
bigger glutamic acid instead of the flexible, small glycine can be assumed to prevent the 
correct formation of the triple helix, which assembles from the C-terminal tail (Figure 1C). 
Although the proband was very young (7 years), the presence of recurrent episodes of 
macrohaematuria may indicate a poor prognosis. 
Digenic autosomal inheritance with linked mutation in trans  
In five of the seven families with COL4A3/COL4A4 mutation combinations, the two 
mutations were definitely linked in trans (Families 1–5; Figures 1, 2). In these families, 
individuals with two heterozygous mutations had more severe phenotypes than those with 
a single heterozygous mutation. Family members having only one mutation in a collagen 
gene were asymptomatic (father in Family 1) or had haematuria (mothers in Families 1, 2 
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and 4; father in Family 2; niece in Family 3) or intermittent hematuria (daughters in Family 
3).  
In the digenic model with mutations linked in trans, the mode of inheritance mimics 
a recessive model, in the sense that the probability of having another child with the same 
genotype is 25%. The main difference is that the classic recessive model is determined by 
the combination of two alleles mutated at the same locus, while the digenic model is 
attributable to two different alleles mutated at two different loci. However, individuals with 
digenic disease have an intermediate phenotype between autosomal dominant and 
autosomal recessive form. 
Digenic autosomal inheritance with linked mutation in cis  
In the other two families with COL4A3/COL4A4 mutation combinations, the two 
mutations were linked in cis (Figure 3). In Families 6 and 7, the inheritance pattern mimics 
an autosomal dominant mode: the probability of having another child with the same 
genotype is 50%, but the phenotype is more severe than expected for the classic 
autosomal dominant form. In fact, subject I:2 of Family 6 and subjects II:1 and I:2 of Family 
7 had CRF at an early age, with two of them progressing towards ESRD at 40 years of 
age, which is unexpected for the autosomal dominant form.21  
Digenic unlinked autosomal/X-linked inheritance 
In Families 8-11, there was a combination of a mutation in the autosomal COL4A4 
gene and in the X-linked gene COL4A5 (Figures 4, 5). In these families, double 
heterozygotes also have a more severe phenotypes than expected in individuals with a 
COL4A4 heterozygous mutation or in COL4A5 carrier females.6,21 In fact, the female I:1 in 
Family 8 had ESRD at the age of 44 years, earlier than expected had she had just one 
mutation in either COL4A4 or COL4A5.  
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In Family 11, in addition to the mutation in COL4A5, two mutations in COL4A4 were 
found, resembling a triallelic inheritance (Figure 5). The proband (II:4) presented with 
intermittent haematuria and proteinuria, and a first genetic testing by Sanger sequencing 
revealed an autosomal recessive form of Alport syndrome due to compound 
heterozygosity at the COL4A4 gene. The first male sib (II:1) had both COL4A4 mutations, 
while three other sibs (II:2; II:3 and II:5) with a similar degree of the disease were carriers, 
as was the last sib who had isolated haematuria. At clinical re-evaluation, the father was 
found to have ESRD, so the proband was re-tested using massively parallel sequencing 
techniques. An additional pathogenic mutation resulting in a Gly substitution at codon 684 
in COL4A5 was identified. Not surprisingly, all sisters were carriers. We suggest that the 
concomitant mutations in two different genes may be associated with a more severe 
clinical picture, even if in this family a follow-up is needed.  
Discussion 
The present study provides evidence that digenic inheritance can occur in Alport 
syndrome as well as classic Mendelian inheritance. Using massively parallel sequencing, 
we investigated 11 families with variable degrees of clinical severity among their members 
who also varied in the genotype of two (or three) loci of two collagen type IV genes. In the 
reported pedigrees, the “two-locus model” explains the variable expressivity of the disease 
within the same family better than simple Mendelian inheritance: the different genotypes at 
two loci, roughly equal in importance, can explain the differences in age at onset of renal 
failure and in the severity of the symptoms. This discovery has implications for genetic 
counselling especially for risk assessment of patients’ relatives, because an erroneous 
definition of the inheritance model may result in incomplete cascade of testing relatives 
with consequent erroneous risk estimations. 
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All missense mutations except two affected glycine residues in the collagenous 
domain. Glycine is a small amino acid essential for making the protein flexible and allowing 
the coiling of the triple helix, building the final shape of the collagenous domain. The other 
two missense mutations were found in the main non-collagenous domain (NC1) relevant 
for the protein’s self-assembly and formation of the irregular polygonal network. One such 
mutation, c.4760C>G in COL4A4, affects an evolutionarily conserved codon.22 A different 
missense mutation having the same effect on the protein’s sequence, p.(Pro1587Arg), was 
recently reported in another Alport syndrome patient.23 The last missense mutation, 
c.4994G>A (p.Cys1665Tyr) in COL4A3, eliminates a cysteine. Cysteine residues are key 
amino acids in the non-collagenous domains because their disulphide bridges are 
important for the globular structure. These observations strengthen the pathogenic 
classification of these changes.  
In our cohort, we identified seven families with associated mutations in COL4A3 and 
COL4A4 genes and four families with associated mutations in COL4A4 and COL4A5. We 
did not find kindreds with digenic inheritance attributable to mutations in COL4A3 and 
COL4A5. This is likely due to the small size of our cohort; however we cannot exclude a 
possible biological mechanism. Present knowledge of basement membranes is based on 
the 1:1:1 model. Each alpha chain (α3, α4 and α5) interacts equally with the other two, 
concurring to form a triple helix. Therefore there is no molecular explanation for missing a 
COL4A3/COL4A5 combination. It is likewise unlikely that this combination gives rise to an 
unrecognisable phenotype.  
In our cohort, double heterozygotes reach ESRD at the age of 40 years (subject I:2 
of Family 6 and I:2 of Family 7) and 44 years (subject I:1 of Family 8). It is interesting to 
note that this is older than the mean age expected in the autosomal recessive form (31 
years) but earlier than expected in the autosomal dominant form (56 years).21,5 This fits 
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well with the stoichiometry of the molecules of the triple helix (Figure 6). In double 
heterozygotes about 75% of triple helix molecules are expected to be defective, which is 
more than 50% in heterozygotes and less than 100% in homozygotes or hemizygotes. 
Pedigree 11 may represent an example of the triallelic form of digenic inheritance. 
This kind of inheritance has been previously proved in Bardet-Biedl syndrome and other 
diseases.24 Triallelic inheritance is defined when any combination of three deleterious 
alleles at two loci, but not three heterozygous mutations at three loci, is sufficient to cause 
the disease. In the case of Family 11, subject II:4 has two mutated alleles at the COL4A4 
locus (M1, M2) in addition to one mutated allele at the COL4A5 locus (M3). In this family 
an accurate follow-up of clinical progression may enhance our understanding of how the 
combination of different mutated alleles contributes to the developing phenotype. While the 
pathogenicity of the splice site mutation in COL4A4 (M1) and of the Gly substitution in the 
collagen domain of COL4A5 (M3) is certain, one could question the pathogenicity of the 
COL4A4 Pro to Arg substitution in the NC1 domain (M2; rs190148408). Two of three 
prediction tools scored this variant as pathogenic, and its reported frequency in the general 
population is 0.3%. Segregation analysis of Family 11 is suggestive of a role of this allele 
in worsening the phenotype. Undoubtedly more data are necessary to exactly define the 
role of this mutation before we can conclude that the pedigree is an example of triallelic 
inheritance.  
In summary, in this paper we provide evidence for a digenic inheritance model for 
Alport syndrome and illustrate three possible segregation models: i) autosomal inheritance 
with linked mutations in trans mimicking the recurrence risk of a recessive disease; ii) 
autosomal inheritance with linked mutations in cis mimicking the recurrence risk of a 
dominant disease; and iii) unlinked autosomal and X-linked inheritance having its own 
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distinctive segregation. While the first case (linked in trans) represents a novelty with 
purely scientific interest, the other two have important implications in genetic counseling.  
In cases of digenic inheritance linked in trans, the prognosis of affected individuals 
and the risk of recurrence for the couple overlap with those of the recessive form (Figure 
7A). For digenic inheritance with linked mutations in cis, the risk of recurrence is the same 
as that of the autosomal dominant disorder, but the prognosis is worse and intermediate 
between the autosomal dominant and autosomal recessive forms (Figure 7B). The 
clinician may need to discuss this with their patients. In digenic unlinked autosomal and X-
linked inheritance, neither recurrence risk nor prognosis fit with any previously known 
Alport model and need to be determined on a case by case basis. Figure 7C illustrates the 
case of segregation through an affected male, hemizygous for an X chromosome mutation 
(COL4A5 gene) and heterozygous for a mutation on chromosome 2 (mutation at either the 
COL4A3 or COL4A4 locus). If only one mutation is detected, for example that on 
chromosome X, the risk of recurrence of the disease is about zero. This risk may increase 
because of the second event reaching up to 50%. In a similar situation with mating with a 
heterozygote, triallelic segregation will appear in the offspring and half of them will have an 
even worse prognosis (Figure 7D). Therefore, the present results are of interest both from 
a scientific point of view and for genetic counselling. Clinical geneticists should be familiar 
with more complex models of inheritance, which could alter the prognosis and recurrence 
risk. 
 
Acknowledgements 
We thank the patients and their families for permitting us to do this study. The 
following physicians are acknowledged for their support: Prof. Grunfeld, Dr Ginglinger, Dr 
Dieterich, Dr Servais. This work was supported in part by a donation in favor of ‘Graziano 
16 
 
and Marco Laurini’ and Alport Syndrome Foundation (to AR) and by the Northern Counties 
Kidney Research Fund (to JAS). The biobank in Siena which furnished genomic DNA is a 
member of the Telethon Network of Genetic Biobanks (project no. GTB12001), funded by 
Telethon Italy. This work was presented at the 2014 conference of the European Society 
of Human Genetics where it was selected as the best scientific contribution to kidney 
disease by the association A.Ma.R.T.I. Onlus (Associazione Malattie Renali Toscana per 
l’Infanzia).  
17 
 
References 
1. Kruegel, J., Rubel, D., Gross, O. (2013). Alport syndrome-insights from basic and 
clinical research. Nat Rev Nephrol. 9, 170-8.  
2. Hudson, B.G., Tryggvason, K., Sundaramoorthy, M., Neilson, E.G. (2003) Alport's 
syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med. 348, 2543–
2556.  
3. Wang, Y., Sivakumar, V., Mohammad, M., Colville, D., Storey, H., Flinter, F., 
Dagher, H., Savige, J. (2014). Clinical and genetic features in autosomal recessive and X-
linked Alport syndrome. Pediatr Nephrol. 29, 391-6. 
4. Longo, I., Porcedda, P., Mari, F., Giachino, D., Meloni, I., Deplano, C., Brusco, A., 
Bosio, M., Massella, L., Lavoratti, G., et al. (2002). COL4A3/COL4A4 mutations: from 
familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int.  61, 
1947-56. 
5. Fallerini, C., Dosa, L., Tita, R., Del Prete, D., Feriozzi, S., Gai, G., Clementi, M., La 
Manna, A., Miglietti, N., Mancini, R., et al. (2014). Unbiased next generation sequencing 
analysis confirms the existence of autosomal dominant Alport syndrome in a relevant 
fraction of cases. Clin Genet.  86, 252-7.  
6. Jais, J.P., Knebelmann, B., Giatras, I., De Marchi, M., Rizzoni, G., Renieri, A., 
Weber, M., Gross, O., Netzer, K.O., Flinter, F., et al. (2003). X-linked Alport syndrome: 
natural history and genotype-phenotype correlations in girls and women belonging to 195 
families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc 
Nephrol. 14, 2603-10.  
7. Artuso, R., Fallerini, C., Dosa, L., Scionti, F., Clementi, M., Garosi, G., Massella, L., 
Epistolato, M.C., Mancini, R., Mari, F., et al. (2012). Advances in Alport syndrome 
diagnosis using next-generation sequencing. Eur J Hum Genet. 20, 50-7.  
8. Savige, J., Gregory, M., Gross, O., Kashtan, C., Ding, J., Flinter, F. (2013). Expert 
guidelines for the management of Alport syndrome and thin basement membrane 
nephropathy. J Am Soc Nephrol. 24, 364-7. 
9. Jais, J.P., Knebelmann, B., Giatras, I., De Marchi, M., Rizzoni, G., Renieri, A., 
Weber, M., Gross, O., Netzer, K.O., Flinter, F., et al. (2000). X-linked Alport syndrome: 
natural history in 195 families and genotype- phenotype correlations in males. J Am Soc 
Nephrol. 11, 649-57. 
18 
 
10. Voskarides, K., Arsali, M., Athanasiou, Y., Elia, A., Pierides, A., Deltas, C. (2012) 
Evidence that NPHS2-R229Q predisposes to proteinuria and renal failure in familial 
hematuria. Pediatr Nephrol. 27, 675-9.  
11. Schäffer, A.A. (2013) Digenic inheritance in medical genetics. J Med Genet. 50, 
641-52. 
12. Kajiwara, K., Berson, E.L., Dryja, T.P. (1994) Digenic retinitis pigmentosa due to 
mutations in the unlinked peripherin/RDS and ROM1 loci. Science 264, 1604–8. 
13. Esposito, T., Sampaolo, S., Limongelli, G., Varone, A., Formicola, D., Diodato, D., 
Farina, O., Napolitano, F., Pacileo, G., Gianfrancesco, F., et al. (2013). Digenic mutational 
inheritance of the integrin alpha 7 and the myosin heavy chain 7B genes causes 
congenital myopathy with left ventricular non-compact cardiomyopathy. Orphanet J Rare 
Dis. 8, 91.  
14. Girirajan, S., Rosenfeld, J.A., Cooper, G.M., Antonacci, F., Siswara, P., Itsara, A., 
Vives, L., Walsh, T., McCarthy, S.E., Baker, C., et al. (2010). A recurrent 16p12.1 
microdeletion supports a two-hit model for severe developmental delay. Nat Genet. 42, 
203-9. 
15. Girirajan, S., Brkanac, Z., Coe, B.P., Baker, C., Vives, L., Vu, T.H., Shafer, N., 
Bernier, R., Ferrero, G.B., Silengo, M., et al. (2011). Relative burden of large CNVs on a 
range of neurodevelopmental phenotypes. PLoS Genet. 7, e1002334. 
16. Morinière, V., Dahan, K., Hilbert, P., Lison, M., Lebbah, S., Topa, A., Bole-Feysot, 
C., Pruvost, S., Nitschke, P., Plaisier, E., et al. (2014). Improving Mutation Screening in 
Familial Hematuric Nephropathies through Next Generation Sequencing. J Am Soc 
Nephrol. ASN.2013080912. [Epub ahead of print]. 
17. Kashtan, C.E. (2004). Familial hematuria due to type IV collagen mutations: Alport 
syndrome and thin basement membrane nephropathy. Curr Opin Pediatr. 16, 177-81. 
18. Stenson, P.D., Ball, E.V., Mort, M., Phillips, A.D., Shiel, J.A,, Thomas, N.S., 
Abeysinghe, S., Krawczak, M., Cooper, D.N. (2003). Human Gene Mutation Database 
(HGMD): 2003 update. Hum Mutat. 21, 577-81.  
19. Crockett, D.K., Pont-Kingdon, G., Gedge, F., Sumner, K., Seamons, R., Lyon, E. 
(2010). The Alport syndrome COL4A5 variant database. Hum Mutat. 31, E1652-7.  
19 
 
20. Hertz JM, Thomassen M, Storey H, Flinter F. (2012) Clinical utility gene card for: 
Alport syndrome. Eur J Hum Genet. 20. 
21. Pescucci, C., Mari, F., Longo, I., Vogiatzi, P., Caselli, R., Scala, E., Abaterusso, C., 
Gusmano, R., Seri, M., Miglietti, N., et al. (2004). Autosomal-dominant Alport syndrome: 
natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int. 65, 1598-603. 
22. Kalluri, R. (2003). Basement membranes: structure, assembly and role in tumour 
angiogenesis. Nature Reviews Cancer 3, 422-433.  
23. Chatterjee, R., Hoffman, M., Cliften, P., Seshan, S., Liapis, H., Jain, S. (2013) 
Targeted Exome Sequencing Integrated with Clinicopathological Information Reveals 
Novel and Rare Mutations in Atypical, Suspected and Unknown Cases of Alport Syndrome 
or Proteinuria. PLoS ONE 8, e76360. 
24. Katsanis, N., Ansley, S.J., Badano, J.L., Eichers, E.R., Lewis, R.A., Hoskins, B.E., 
Scambler, P.J., Davidson, W.S., Beales, P.L., Lupski, J.R. (2001). Triallelic inheritance in 
Bardet-Biedl syndrome, a Mendelian recessive disorder. Science. 293, 2256-9.  
20 
 
Legends to Figures 
 
Figure 1 Molecular and segregation analysis of Family 1 
A) Pedigree: the mutated alleles are linked in trans and the mode of inheritance is digenic 
autosomal. wt, wild type allele. B)Screenshots from the GS Amplicon Variant Analyzer 
software showing the position of the COL4A4 missense mutation c.1553G>A 
(p.Gly518Glu; M1) and the COL4A3 splice site variant c.2746+1G>T (M2) and. The upper 
histograms indicate the percentage of variation. In the lower panels, reads from different 
directions are displayed and the mutated base is highlighted. C) Locations of these 
mutations on the a3-a4-a5 triple helix of collagen.  
 
Figure 2 Pedigrees of three other families having digenic autosomal inheritance with 
mutations in COL4A3 and COL4A4 linked in trans. A) Family 2. B) Family 3. C) Family 4. 
D) Family 5. CRF, chronic renal failure; SNHL, sensorineural hearing loss; ESRD, end-
stage renal disease.  
 
Figure 3 Families with digenic autosomal inheritance with mutations in COL4A3 and 
COL4A4 linked in cis. A) Family 6. B) Family 7. CRF, chronic renal failure; SNHL, 
sensorineural hearing loss; ESRD, end-stage renal disease 
 
Figure 4 Families with mutations in COL4A4 and COL4A5, with digenic unlinked 
autosomal and X-linked inheritance. A) Family 8. B) Family 9. C) Family 10. SNHL, 
sensorineural hearing loss; ESRD, end-stage renal disease. 
 
Figure 5 Pedigree of Family 11 with a triallelic form of digenic inheritance, with mutations 
in COL4A4 and COL4A5. ESRD, end-stage renal disease. 
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Figure 6 Triple helix combinations of defective alpha chains.   
A) In heterozygotes, about 50% of triple helix molecules are expected to be defective. B) 
In homozygotes or hemizygotes, 100% of triple helix molecules are expected to be 
defective. C) In double heterozygotes, about 75% of triple helix molecules are expected to 
be defective. 
 
Figure 7 Three possible segregation models of digenic inheritance in Alport syndrome. 
A) Digenic autosomal inheritance with linked mutations in trans mimicking a recessive 
inheritance disease. B) Digenic autosomal inheritance with linked mutations in trans 
mimicking a dominant inheritance. C) Unlinked autosomal and X-linked inheritance having 
its own particular segregation. D) Trialleic inheritance as observed in Family 11. 
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Table 1. Molecular features and predicted pathogenicity of 23 mutations in collagen IV genes, found in 11 patients with Alport syndrome 
 
      
Pathogenicity* 
 
DNA variant Type 
Exon 
(intron) 
number 
dbSNP 
reference ID 
Predicted effect  
on the protein 
Collagen 
domain affected 
(for missense 
mutation) 
SIFT (score)
a
 
Mutation taster 
(p value)
b
 
PolyPhen2 (score)
c
 
COL4A3 
 
del ex 1 Deletion 1 - Whole gene deletion NA NA NA NA 
 
c.898G>A Missense 16 - p.Gly300Arg Collagenous Deleterious (0) Disease-causing (1) Probably damaging (1) 
 
c.1504+1G>A 
Misplicing 
Lost 5′ splice site  
(23) -
16
 p.? NA NA NA NA 
 
c.1558G>C Missense 24 Pending
16
 p.Gly520Arg Collagenous Deleterious (0) Disease-causing (1) Probably damaging (1) 
 
c.2065G>A Missense 28 Pending
16
 p.Gly689Arg Collagenous Deleterious (0) Disease-causing (1) Probably damaging (1) 
 
c.2746+1G>T 
Misplicing 
Lost 5′ splice site  
(33) - p.? NA NA NA NA 
 
c.4994G>A Missense 52 rs376550779 p.Cys1665Tyr NC1 Deleterious (0) Disease-causing (1) Probably damaging (1) 
COL4A4 
 
c.[1-?_192+?del] Deletion 1-4 -
16
 Whole gene deletion NA NA NA NA 
 
c.1293_1310del In-frame deletion 20 - p.Lys434_Gly439del Collagenous NA NA NA 
 
c.1459+1G>A 
Misplicing 
Lost 5′ splice site 
(21) - p.? NA NA NA NA 
 
c.1553G>A Missense 22 - p.Gly518Glu Collagenous Deleterious (0) Disease-causing (1) Probably damaging (1) 
 
c.1623+5G>T 
Misplicing  
Lost 5′ splice site  
(22) - p.? NA NA NA NA 
 
c.2075G>T Missense 27 Pending
16
 p.Gly692Val Collagenous Deleterious (0) Disease-causing (1) Probably damaging (1) 
 
c.2164G>A Missense 27 - p.Gly722Ser Collagenous Deleterious (0) Disease-causing (1) Probably damaging (1) 
 
c.2906C>G
22
 Nonsense 32 rs35138315  p.Ser969X Collagenous NA NA NA 
 
c.3452G>C Missense 37 rs371803356 p.Gly1151Ala Collagenous Deleterious (0) Disease-causing (1) Probably damaging (1) 
 
c.3817+1G>T 
Misplicing 
Lost 5′ splice site  
(40) - p.? NA NA NA NA 
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c.4698delT Frame shift 47 -
16
 p.Cys1566Trpfs*37 NC1 NA NA NA 
 
c.4760C>G Missense 47 rs190148408
d
 p.(Pro1587Arg) NC1 Deleterious (0.01) Polymorphism (1) 
Probably damaging 
(0.913) 
COL4A5 
 
c.1931G>A Missense 25 Pending
16
 p.Gly644Asp Collagenous Deleterious (0) Disease-causing (1) Probably damaging (1) 
 c.2051G>T Missense 27 rs104886160
e
  p.Gly684Val Collagenous Deleterious (0) Disease-causing (1) Probably damaging (1) 
 c.2858G>T  Missense 33 rs78972735
e, f 
 p.Gly953Val Collagenous Deleterious (0) Disease-causing (1) Probably damaging (1) 
 c.4042G>A Missense 46 - p.Gly1348Arg Collagenous Deleterious (0) Disease-causing (1) Probably damaging (1) 
*Pathogenicity predicted using Alamut software v.2.3 (Interactive Biosoftware, Rouen, France). a Substitutions with normalized 
probabilities <0.05 are predicted to be deleterious, those ≥0.05 are predicted to be tolerated. b P value indicates the security of the 
prediction as either ‘disease-causing’ or ‘polymorphism’, with 1 being most secure. c Benign, possibly damaging, and probably damaging 
correspond to posterior probability intervals [0, 0.2], (0.2, 0.85), and [0.85, 1], respectively. d Minor allele (C) frequency/count=0.003/6; e 
dbSNP clinical significance, pathogenic; f Minor allele (T) frequency/count =0.003/5. 
NA, not applicable.  
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Table 2. Clinical characteristics and collagen gene mutations in 11 patients with Alport syndrome and their family members 
Family 
number 
Family 
member 
(pedigree 
position) 
Sex Age, years
a
 
Kidney disease 
(age, years
b
) 
Hearing 
loss (age, 
years
c
) 
Ocular 
lesions 
Mutation (nucleotide change; effect on protein) 
COL4A3 COL4A4 COL4A5 
1 
Proband 
(II:2) 
M 7 
Macrohaematuria 
(4) 
No No c.2746+1G>T; p.? c.1553G>A; p.Gly518Glu None 
1 
Mother  
(I:1) 
F 45 Microhaematuria NA No c.2746+1G>T; p.? Variant not present NT 
1 
Father 
(I:2) 
M 43 
Ureteropelvic 
junction obstruction 
NA NA Variant not present c.1553G>A; p.Gly518Glu  NT 
2 
Proband 
(II:1) 
F 36 Microhaematuria  No No 
c.898G>A; 
p.Gly300Arg 
c.3452G>C; p.Gly1151Ala None 
2 
Mother 
(I:1) 
F NA Microhaematuria NA NA 
c.898G>A; 
p.Gly300Arg 
Variant not present NT 
2 
Maternal 
grandfather 
M NA ESRD (80) NA NA NA NA NA 
2 
Father 
(I:2) 
M NA Microhaematuria  NA NA Variant not present c.3452G>C; p.Gly1151Ala NT 
3 
Proband 
(I:2) 
M 55 Proteinuria, CRF Yes (39) NA 
c.1558G>C; 
p.Gly520Arg 
c.4698delT; p.Cys1566Trpfs*37 None 
3 Mother F 
Dead, 88, 
cancer 
None No NA NA NA NT 
3 
Maternal 
uncle 
M 
Dead, 45, 
ESRD 
ESRD (<45) NA NA NA NA NT 
3 
Sister 
(I:1) 
F 60 
Preemptive renal 
transplantation (50) 
Yes NA 
c.1558G>C; 
p.Gly520Arg 
c.4698delT; p.Cys1566Trpfs*37 NT 
3 Father M 
Dead, 
cancer 
None No NA NA NA NA 
3 
Daughter 
(II:2) 
F 23 
Intermittent 
haematuria 
No NA Variant not present c.4698delT; p.Cys1566Trpfs*37 NT 
25 
 
3 
Daughter 
(II:3) 
F 20 
Intermittent 
haematuria 
No NA 
c.1558G>C; 
p.Gly520Arg 
Variant not present NT 
3 
Niece 
(II:1) 
F 28 Haematuria NA NA 
c.1558G>C; 
p.Gly520Arg 
Variant not present NT 
4 
Proband 
(III:1) 
F 36 
Haematuria, 
proteinuria 
No NA c.1504+1G>A; p.? 
c.1293_1310del; 
p.Lys434_Gly439del  
None 
4 
Mother 
(II:1) 
F 64 Haematuria No NA c.1504+1G>A; p.?  Variant not present NT 
4 
Father 
(II:2) 
M 80 ESRD (68) No NA Variant not present 
c.1293_1310del; 
p.Lys434_Gly439del  
NT 
4 
Paternal 
aunt 
(II:3) 
F 76 ESRD (64) No NA Variant not present 
c.1293_1310del; 
p.Lys434_Gly439del  
NT 
4 
Paternal 
granduncle 
(I:3) 
M Dead, ~70 Haematuria No NA NA NA NA 
4 
Paternally 
related 
M 48 Haematuria No NA Variant not present 
c.1293_1310del; 
p.Lys434_Gly439del  
NT 
4 
Paternal 
grandaunt 
(I:4) 
F Dead 
Haematuria, 
proteinuria, ESRD 
No NA NA NA NA 
4 
Paternally 
related 
M 47 
Haematuria, 
proteinuria, CRF 
(47) 
No NA Variant not present 
c.1293_1310del; 
p.Lys434_Gly439del  
NT 
4 
Paternally 
related 
F 80 
Haematuria, 
proteinuria, CRF 
(70) 
No NA Variant not present 
c.1293_1310del; 
p.Lys434_Gly439del  
NT 
4 
Paternally 
related 
M 69 CRF (69) No NA Variant not present 
c.1293_1310del; 
p.Lys434_Gly439del  
NT 
4 
Paternally 
related 
F NA CRF (80) No NA Variant not present 
c.1293_1310del; 
p.Lys434_Gly439del  
NT 
4 
Paternally 
related 
F 51 ESRD (50) No NA Variant not present 
c.1293_1310del; 
p.Lys434_Gly439del  
NT 
4 
Paternally 
related 
NA NA ESRD (60) No NA NA NA NA 
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5 
Proband 
(II:1) 
F 3 Macrohaematuria No No 
c.2065G>A; 
p.Gly689Arg 
c.1459+1G>A; p.? None 
5 
Mother 
(I:1) 
F NA Haematuria No NA 
c.2065G>A; 
p.Gly689Arg 
Variant not present NT 
5 
Father 
(I:2) 
M NA None No NA Variant not present c.1459+1G>A; p.? NT 
6 
Proband 
(II:1) 
F 37 
Intermittent 
haematuria 
NA NA 
c.4994G>A; 
p.Cys1665Tyr 
c.2906C>G; p.Ser969X None 
6 
Mother 
(I:1) 
F NA None NA NA Variant not present Variant not present NT 
6 
Father 
(I:2) 
M Dead 
CRF (21); ESRD 
(40) 
Yes NA NA NA NA 
7 
Proband 
(II:1) 
M 45 
Haematuria, 
proteinuria, CRF 
Yes (32)
d
 NA 
del exon 1 (same 
allele) 
c.[1-?_192+?del];[=](del ex1-4) None 
7 
Son 
(III:1) 
M 19 None No NA Variant not present Variant not present None 
7 
Father 
(I:2) 
M 
Dead, 40, 
ESRD 
ESRD (<40) NA NA NA NA NA 
7 
Paternal 
uncle 
(I:1) 
M 
Dead, 61, 
ESRD 
ESRD (<61) NA NA NA NA NA 
8 
Proband 
(I:1) 
F 54 ESRD (44) Yes Yes None c.3817+1G>T; p.? c.2858G>T; p.Gly953Val  
8 
Son 
(II:1) 
M 17 Haematuria NA NA NT c.3817+1G>T; p.? Variant not present 
9 
Proband 
(II:1) 
F 45 
Haematuria, 
proteinuria 
Yes (34) NA None c.2075G>T; p.Gly692Val c.1931G>A; p.Gly644Asp 
9 
Mother 
(I:1) 
F 69 
Haematuria, 
proteinuria during 
pregnancies 
No
e
 NA NT Variant not present c.1931G>A; p.Gly644Asp 
9 Son M 11 
Microalbuminuria 
(91 mg/l) 
No NA NT c.2075G>T; p.Gly692Val Variant not present 
9 Son M 9 None No NA NT Variant not present Variant not present 
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9 
Paternal 
nephew 
M NA 
Possible renal 
disease 
Yes NA NA NA NA 
10 
Proband 
(II:1) 
M 26 
Haematuria, 
proteinuria 
No No None c.2164G>A; p.Gly722Ser c.4042G>A; p.Gly1348Arg  
10 
Father 
(I:2) 
M 65 NA No NA NT c.2164G>A; p.Gly722Ser Variant not present 
10 
Mother 
(I:1)  
F 55 NA No NA NT Variant not present Variant not present 
11 
Proband 
(II:4) 
F 13 
Intermittent 
haematuria, 
proteinuria 
No NA None 
c.1623+5G>T; p.? 
c.4760C>G; p.(Pro1587Arg) 
c.2051G>T; p.Gly684Val  
11 
Mother 
(I:1) 
F 32 
Haematuria, 
proteinuria 
No NA NT c.1623+5G>T; p.?  Variant not present 
11 
Father 
(I:2) 
M 33 ESRD (25) Yes Yes NT c.4760C>G; p.(Pro1587Arg)  c.2051G>T; p.Gly684Val 
11 
Brother 1 
(II:1) 
M 17 
Haematuria, 
proteinuria 
No NA NT 
c.1623+5G>T; p.? 
 c.4760C>G; p.(Pro1587Arg)  
Variant not present 
11 
Brother 2 
(II:2) 
M 17 
Haematuria, 
proteinuria 
No NA NT c.4760C>G; p.(Pro1587Arg) Variant not present 
11 
Sister 1 
(II:3) 
F 14 
Haematuria, 
microalbuminuria 
No NA NT c.1623+5G>T; p. ? c.2051G>T; p.Gly684Val 
11 
Sister 2 
(II:5) 
F 9 
Haematuria, 
proteinuria 
No NA NT c.1623+5G>T; p.? c.2051G>T; p.Gly684Val 
11 
 
Sister 3 
(II:6) 
F 5 Haematuria No NA NT c.1623+5G>T; p.? c.2051G>T; p.Gly684Val 
          
 
a
 Cause of death indicated when available; 
b
 Age at diagnosis or intervention; 
c
 Age at diagnosis; 
d
  -40 dB; 
e
  Tested at 65 years 
NA, data missing or DNA not available for analysis; NT, gene not tested in relatives because not mutated in proband; CRF, chronic renal failure; ESRD, end-stage 
renal disease 
 
 
M1 
M2 
7 y 
Microhaematuria 
Macrohaematuria since 4y 
45 y 
Microhaematuria 
wt 
wt 
M1 wt 
wt wt M2 
wt 
wt 
wt 
M1 = p.Gly518Glu 
M2 = c.2746+1G>T 
a 
b c 
Family 1 
2 II 1 
2 1 I 
M1 = COL4A4 p.Gly1151Ala 
M2 = COL4A3 p.Gly300Arg 
Microhaematuria 
M2 
wt 
wt 
M1 wt 
wt 
wt 
wt 
55 y 
CRF 
SNHL 
M1 
M2 
wt 
wt 
M1 
M2 
wt 
wt 
wt 
wt M1 
wt 
Family 2 
Family 3 
36 y 
Microhaematuria 
M1 
M2 
wt 
wt 
M2 = COL4A3 p.Gly520Arg 
M1 = COL4A4 p.Cys1566Trpfs*37 
2 I 1 
2 
2 
1 
1 I 
II 
II 
Microhaematuria 
M2 
wt wt 
wt 
3 
M2 
wt wt 
wt 
1 
20 y 
Intermittent 
haematuria 
60 y 
Preemptive 
renal 
transplantation 
28 y 
Micro-
haematuria 
23 y 
Intermittent 
haematuria 
M2 = COL4A3 1504+1G>A 
M1 = COL4A4 p.Lys434_Gly439del 
wt 
M2 
wt 
wt 
Family 4 
M1 
M2 
wt 
wt 
M1 
wt 
wt 
wt 
M1 
wt 
wt 
wt 
M1 
wt 
wt 
wt 
ESRD 
36 y 
Haematuria 
Proteinuria 
Haematuria 
3 
1 
1 I 
2 3 1 
2 
ESRD 
II 
III 
ESRD 
4 
40 y 
CRF at 20 
M1 = COL4A4 p.Ser969X 
M2 = COL4A3 p.Cys1665Tyr 
37 y 
Intermittent 
haematuria 
45 y 
Haematuria 
proteinuria 
CRF, SNHL 
40 y ESRD 
M2 = COL4A3 del ex1 
M1 = COL4A4 del ex1-4 
M1 
M2 
wt 
wt 
wt 
wt 
wt 
wt 
M1 
M2 
wt 
wt 
wt 
wt 
wt 
wt 
Family 5 Family 6 
3 
1 
1 
II 
2 
1 
1 
2 
1 II 
I 
III 
I 
wt 
M2 = COL4A5 p.Gly1348Arg 
M1 = COL4A4 p.Gly722Ser 
26 y 
Haematuria 
proteinuria 
M1 wt 
M2 = COL4A5 Gly644Asp 
M1 = COL4A4 Gly692Val 
69 y 
Micro-
haematuria 
45 y 
Haematuria 
proteinuria 
SNHL 
wt 
M2 
wt 
wt 
M1 
wt M2 
wt 
M2 = COL4A5 p.Gly953Val  
M1 = COL4A4 c.3817+1G>T  
54 y 
ESRD at 44 
SNHL 
17 y 
Haematuria 
M1 wt 
wt 
M1 
wt 
M2 
Family 9 Family 7 
Family 8 
1 
2 1 
1 
2 1 
1 
2 1 
I 
 
II 
 
I 
 
II 
 
I 
 
II 
 
M1 wt 
M2 
wt wt 
wt wt 
wt 
M1 
M3 = COL4A5  p.Gly684Val 
M1 = COL4A4  c.1623+5G>T 
ESRD 
Haematuria 
proteinuria 
Haematuria 
proteinuria 
Haematuria Haematuria 
microalbuminuria 
Intermittent 
Haematuria 
Proteinuria 
Haematuria 
Proteinuria 
M2 = COL4A4  p.Pro1587Arg 
wt M3 
M1 
wt 
wt 
wt M3 
M1 
wt M3 
M2 
wt M3 
wt M1 M2 
M2 
M3 
wt wt 
wt 
wt wt M1 
wt 
Family 10 
5 
2 1 
II 
 
2 1 6 4 
I 
 
Haematuria 
Proteinuria 
3 
M1 M2 
wt 
M
1  
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